Triglycerides are more important in atherosclerosis than epidemiology has suggested

Atherosclerosis

Volumn 141, Issue SUPPL. 1, 1998, Pages

  Durrington, P N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CHD; HDL; LDL; Serum cholesterol

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; STATIN; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; HYPERTRIGLYCERIDEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031775430     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00219-6     Document Type: Conference Paper

References (36)

1. Gofman JW, de Lalla O, Glazier F, Freeman NK, Nicholas AV, Strisower EH, Tamplin AR. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary artery disease. Plasma 1954;2:413-84.
2. Carlson LA, Böttiger LE. Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm Prospective Study Lancet 1972;1:865-8.
3. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
4. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart disease. Lancet 1973;1:954-9.
5. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidaemia in coronary heart disease 1. Lipid levels in 500 survivors of myocardial infarction. J Clin Investig 1973;52:1533-43.
6. Moorjani S, Gagne C, Lupien PJ, Brunn D. Plasma triglyceride related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolaemia. Metabolism 1986;35:311-6.
7. Hulley SB, Roseman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. New Engl J Med 1980;302:1383-9.
8. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
9. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimations of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. Brit Med J 1994;308:363-6.
10. Durrington PN. Biological variation in serum lipid concentrations. Scand J Clin Lab Investig 1990;50(Suppl 198):86-91.
11. Abbot RD, Carroll RJ. Interpreting multiple logistic regression coefficients in prospective observations studies. Am J Epidemiol 1984;119:830-6.
12. Phillips AN, Davey Smith G. How independent and 'independent' effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:1223-31.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Survival Study. Lancet 1994;344:1383-9.
14. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl J Med 1995;333:1301-7.
15. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9.
16. Burr ML, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;1:757-61.
17. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351-64.
18. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. Report of the Program on the Surgical Control of Hyperlipidaemia (POSCH). New Engl J Med 1990;323:946-55.
19. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study results reported at the American Heart Association, Orlando 1997.
20. Committee of Principal Investigation. Report on a co-operative trial on primary prevention of ischaemic heart disease using clofibrate. Brit Heart J 1978;40:1069-118.
21. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
22. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl J Med 1987;317:1237-45.
23. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Brit Med J 1994;308:367-73.
24. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995;6:209-14.
25. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post-infarction patients. Lancet 1996;347:849-53.
26. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Investig 1991;88:1785-92.
27. Gianturco SH, Ramprasad MP, Lin AH-Y, Song R, Bradley WA. Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells. J Lipid Res 1994;35:1674-87.
28. Galeano NF, Milne R, Marcel YL, Walsh MT, Levy E, Ngn'yen TD, et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 1994;269:511-9.
29. De Graaf J, Hak-Lemmers H, Hectors M, Demacker P, Hendriks J, Statenhof AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein sub-fraction in healthy subjects. Arterioscler Thromb 1991;11:298-306.
30. Chait A, Brazg R, Tribble D, Krauss R. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
31. Hokanson JE, Austin MA, Brunzell JD. Measurement and clinical significance of low-density lipoprotein subclasses. In: Rifai N, Warnick GR, Dominczak MH, editors. Handbook of Lipoprotein Testing. Washington: AACC Press, 1997:267-82.
32. Bhatnagar D, Durrington PN, Mackness MI, Arrol S, Winocour PH, Prais H. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis 1992;92:49-57.
33. Gaw A, Packard CJ, Caslake MJ, Griffin BA, Lindsay GM, Thomson J, et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994;108:137-48.
34. Channon KM, Clegg RJ, Bhatnagar D, Ishola M, Arrol S, Durrington PN. Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. Atherosclerosis 1990;80:217-26.
35. Durrington PN. Hyperlipidaemia. Diagnosis and Management. 2nd Ed. Oxford: Butterworth-Heinemann, 1995.
36. Simons LA. Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 1986;57:5G-10.